FDA Drug · D-0052-2027

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.

Class II · Ongoing

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Affected lots / codes — check yours against thisLot # 24W06, Exp: 11/30/2026

Recalling firm: Pfizer, Manhattan, NY
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 15,815 100-count bottles
Distribution: US Nationwide and Puerto Rico
Recall initiated: September 29, 2026
Classified: October 16, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0052-2027%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →